Ken Persen - Heartbeam Chief Officer
| BEAT Stock | USD 3.06 0.21 7.37% |
Insider
Ken Persen is Chief Officer of Heartbeam
| Address | 2118 Walsh Avenue, Santa Clara, CA, United States, 95050 |
| Phone | 408 899 4443 |
| Web | https://www.heartbeam.com |
Ken Persen Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ken Persen against Heartbeam stock is an integral part of due diligence when investing in Heartbeam. Ken Persen insider activity provides valuable insight into whether Heartbeam is net buyers or sellers over its current business cycle. Note, Heartbeam insiders must abide by specific rules, including filing SEC forms every time they buy or sell Heartbeam'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ken Persen over a year ago Acquisition by Ken Persen of 60000 shares of Heartbeam subject to Rule 16b-3 |
Heartbeam Management Efficiency
The company has return on total asset (ROA) of (0.6975) % which means that it has lost $0.6975 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1362) %, meaning that it created substantial loss on money invested by shareholders. Heartbeam's management efficiency ratios could be used to measure how well Heartbeam manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.9 in 2024. Return On Capital Employed is likely to gain to -0.91 in 2024. Change To Liabilities is likely to gain to about 1.9 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 16.3 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Mary Modahl | American Well Corp | 57 | |
| Claus Jensen | Teladoc | N/A | |
| Tina Hunt | Veeva Systems Class | 53 | |
| Deborah Jackson | American Well Corp | 69 | |
| Richard Friesner | Schrodinger | 71 | |
| Courtney McLeod | Teladoc | N/A | |
| Eric Esq | 10X Genomics | 57 | |
| Derek Ross | American Well Corp | 48 | |
| Perry Gold | Doximity | N/A | |
| Peter Anevski | Progyny | 57 | |
| Raj Beri | Goodrx Holdings | 49 | |
| Glen Tullman | Teladoc | N/A | |
| Babak Azad | Goodrx Holdings | 51 | |
| Serge Saxonov | 10X Genomics | 47 | |
| Tim Conway | American Well Corp | N/A | |
| Ido MD | American Well Corp | 59 | |
| Deval Patrick | American Well Corp | 63 | |
| Paul Jorgensen | Doximity | 53 | |
| Mark Livingston | Progyny | 58 | |
| Jim Rivas | Doximity | N/A | |
| Bradford Gay | American Well Corp | 47 | |
Management Performance
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.7 |
Heartbeam Leadership Team
Elected by the shareholders, the Heartbeam's board of directors comprises two types of representatives: Heartbeam inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Heartbeam. The board's role is to monitor Heartbeam's management team and ensure that shareholders' interests are well served. Heartbeam's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Heartbeam's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Branislav Vajdic, President, Founder | ||
| FACC MD, Chief Officer | ||
| Timothy Cruickshank, Chief Officer | ||
| Richard Brounstein, CFO Treasurer | ||
| Richa Gujarati, Senior Product | ||
| Kenneth Persen, Chief Officer | ||
| Richard Ferrari, Executive Chairman | ||
| Robert Eno, President Officer | ||
| Ken Persen, Chief Officer | ||
| Jon Hunt, Exec Officer |
Heartbeam Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Heartbeam a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.7 | ||||
| Current Valuation | 70.23 M | ||||
| Shares Outstanding | 26.67 M | ||||
| Shares Owned By Insiders | 29.24 % | ||||
| Shares Owned By Institutions | 8.73 % | ||||
| Number Of Shares Shorted | 76.14 K | ||||
| Price To Earning | 149.92 X | ||||
| Price To Book | 15.83 X | ||||
| EBITDA | 675 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Heartbeam Stock Analysis
When running Heartbeam's price analysis, check to measure Heartbeam's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heartbeam is operating at the current time. Most of Heartbeam's value examination focuses on studying past and present price action to predict the probability of Heartbeam's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heartbeam's price. Additionally, you may evaluate how the addition of Heartbeam to your portfolios can decrease your overall portfolio volatility.